The urgent need to empower rare disease organizations in China: an interview-based study

Xuefeng Li, Zijuan Lu, Jianyong Zhang, Xiang‐Yu Zhang, Zhang Shu, Jincheng Zhou, Bingzhe Li, Li OuOrphanet 2020 · DOI

Abstract

Due to lack of support and rare disease awareness, patient organizations in China are still in the early phase. To empower these patient organizations, the interviewees' recommendations, including legislating orphan drug act and releasing official definition of rare diseases, should be considered by the government and legislators.

Introduction

While individual rare diseases affect small numbers of people, their collective impact is significant, touching nearly 10% of the global population. In many Western nations, patient organizations (POs) serve as vital engines for drug development and legislative advocacy. In China, however, the landscape is markedly different. Patients often endure a "diagnostic odyssey" due to low clinical awareness, and even after diagnosis, they face significant barriers to accessing treatment, which is frequently excluded from national insurance schemes. This study aims to quantify the unmet needs of Chinese POs and provide evidence-based recommendations to bridge the gap between China and the international rare disease community.

Methods

The researchers conducted a qualitative, interview-based study involving 28 representatives from distinct patient organizations across China. These organizations represent a diverse range of conditions, including Phenylketonuria (PKU), Acromegaly, Duchenne Muscular Dystrophy (DMD), and Hemophilia. Data was collected through one-on-one phone interviews lasting 1–2 hours, utilizing 18 primarily open-ended questions to capture the nuanced experiences of these advocacy groups.

Key Insights: The Landscape of Chinese POs

The study revealed several systemic challenges that keep Chinese POs in a precarious "early phase":

  • The WeChat Ecosystem: Unlike international counterparts with robust digital infrastructures, 100% of the surveyed POs rely on WeChat for survival. While effective for immediate communication, this reliance complicates the systematic storage and retrieval of medical information.
  • Registration and Funding: Only 5 of the 28 organizations were officially registered. The "Catch-22" is that registration is difficult to obtain and offers few tangible benefits. Consequently, 60.7% of these organizations have no formal funding, often relying on founders' personal incomes.
  • Policy Gaps: The absence of a statutory definition for "rare disease" and a lack of an "Orphan Drug Act" create significant hurdles. Without market exclusivity or tax incentives, pharmaceutical companies have little motivation to bring imported treatments to the Chinese market.

Key Results and Recommendations

The quantitative findings from the interviews highlight a significant disconnect between patient needs and available resources. A primary hurdle for 71.4% of POs is the lack of public awareness, followed by financial constraints (67.9%). Notably, only 3.6% of organizations reported receiving support from the central government.

Activities, challenges, support received, and recommendations of rare disease patient organizations in China.

To address these gaps, the interviewees provided clear policy recommendations:

  • 82.1% advocated for special insurance programs for rare diseases.
  • 78.6% recommended stimulating domestic research.
  • 71.4% urged the legislation of an "Orphan Drug Act" to incentivize therapy development.

Conclusion

While this study provides a critical roadmap for empowering Chinese POs, it is limited by its sample size and potential selection bias toward more active organizations. Future research should involve larger-scale quantitative surveys and longitudinal studies to track the impact of the "First National List of Rare Diseases" on patient outcomes. Legislators must consider these recommendations to ensure that rare disease patients in China are no longer left behind.

Summary updated

Abstract

Due to lack of support and rare disease awareness, patient organizations in China are still in the early phase. To empower these patient organizations, the interviewees' recommendations, including legislating orphan drug act and releasing official definition of rare diseases, should be considered by the government and legislators.
BibTeX
@inproceedings{li2020urgent,
  author = {Xuefeng Li and Zijuan Lu and Jianyong Zhang and Xiang‐Yu Zhang and Zhang Shu and Jincheng Zhou and Bingzhe Li and Li Ou},
  title = {{The urgent need to empower rare disease organizations in China: an interview-based study}},
  booktitle = {Orphanet},
  year = {2020},
  doi = {10.1186/s13023-020-01568-5},
}
Figure